Anthony Scolaro was approached by two FBI agents on November 2, 2009 who told him that they had information that he had traded on inside information related to the healthcare company Axcan (Nasdaq:AXCA). He got a lawyer, William Brodsky, who...
Just a few months after Axcan swept in to buy up the San Diego-based Mpex and its lead antibiotic program, the former CEO of the developer has successfully spun out the rest of the pipeline into a new company dubbed Rempex and snagged venture...
A trader whose phone conversations were the first known to be monitored secretly by federal agents in the insider-trading investigation related to the Galleon Group hedge fund pleaded guilty in the case.
Eurand agreed to be acquired by Axcan Holdings for $583 million, after an "extended auction process" for the Netherlands specialty pharmaceutical company.
Axcan Holdings has struck a deal to buy Eurand for $583 million. Shareholders are in line for $12 a share, a meager 9.4 percent premium over yesterday's close. "The last several years have seen Eurand evolve" from a licensing and drug developer...
Oops! Unable to complete your request. Please refresh your browser.